Alemtuzumab and asthenia Patient Reports February 13, 2012

Alemtuzumab Side Effects Report #5971708-1
Alemtuzumab side effect was reported by a Physician from GERMANY on Nov 10, 2008. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTARABINE. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #6119038-1
Alemtuzumab side effect was reported by a Physician from GERMANY on Mar 10, 2009. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTOSINE ARABINOSIDE. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #6119104-0
Alemtuzumab side effect was reported by a Physician from GERMANY on Mar 10, 2009. Female patient, 56 years of age, was diagnosed with t-cell lymphoma and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blood potassium decreased, diarrhoea, fatigue, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, CARMUSTINE, ETOPOSIDE, CYTARABINE. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #5732705-4
Alemtuzumab side effect was reported by a Physician from GERMANY on Apr 25, 2008. Female patient, 70 years of age, weighting 167.6 lb, was diagnosed with chronic lymphocytic leukaemia recurrent, antiviral prophylaxis, antibiotic prophylaxis and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, hypertension, pyrexia. Alemtuzumab dosage: unknown. During the same period patient was treated with FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, VALTREX, COTRIM, PARACETAMOL, TAVEGIL. Patient recovered.